Reuters logo
BRIEF- GSK's Promacta/Revolade granted breakthrough therapy designation by FDA
February 3, 2014 / 10:43 AM / 4 years ago

BRIEF- GSK's Promacta/Revolade granted breakthrough therapy designation by FDA

Feb 3 (Reuters) - GlaxoSmithKline Plc : * GSK gains FDA breakthrough therapy designation for Promacta/Revolade (eltrombopag) for severe aplastic anaemia * Designation based on results from study in 43 heavily pretreated patients

with insufficient response to ist *

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below